Europe Latent TB Detection Market to Grow at a CAGR of 4.7% to reach US$ 420.88 Million from 2020 to 2027

The Europe latent TB detection market is expected to grow from US$ 304.39 million in 2020 to US$ 420.88 million by 2027; it is estimated to grow at a CAGR of 4.7% from 2020 to 2027.

The UK, Germany, France, Italy, and Spain are major economies in Europe. Rising government initiatives to promote tuberculosis detection is expected to surge the market growth. The disease disproportionally affects the poor, vulnerable, undernourished, and marginalized people. Evidence from various sources such as World Health Organization (WHO) and the United Nations (UN) shows that countries such as Germany and the UK are highly populated with patients suffering from TB. Thus, the government bodies in these countries are undertaking and adopting certain schemes and initiatives in containing the disease.  Furthermore, countries of the Europe region are giving significant importance in combating TB by undertaking various funding programs. The UK government is one of the largest donor of the Global Fund to fight AIDS, tuberculosis, and malaria. Thus, the financial and medical assistance from the governments for fighting the disease and promoting the diagnosis of TB is providing a lucrative scenario for the growth of the Europe market.

In case of COVID-19, Europe is highly affected specially France followed by Spain, Italy, and Germany. The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day now than they were during the first wave earlier this year. Lockdowns are being reintroduced in UK, Spain and Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, the government of many countries is working towards scaling up testing capacity, which is restricting the growth of the market. The COVID-19 pandemic and associated response have impacted healthcare services globally, severely disrupting care for many communicable diseases such as tuberculosis TB. Laboratory diagnostic services, considered a cornerstone of any country's capacity to manage TB, are likely to be severely impacted by the COVID-19 pandemic due to re-allocation of resources. In England, compared with 2019, TB notifications decreased by 16.5% during April and by 37.3% during May 2020; the LTBI program was paused in response to COVID-19 in March.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe latent TB detection market. The Europe latent TB detection market is expected to grow at a good CAGR during the forecast period. 

Europe Latent TB Detection Market Segmentation 

Europe Latent TB Detection Market – By Test

• Tuberculin Skin Test (TST)
• Interferon Gamma Released Assay (IGRA)

Europe Latent TB Detection Market – By End User

• Hospitals
• Diagnostic Centers
• Laboratories
• Others

Europe Latent TB Detection Market, by Country

• Germany
• UK
• France
• Italy  
• Spain  
• Rest of Europe

Europe Latent TB Detection Market -Companies Mentioned

• Abbott
• ARKRAY, Inc.
• BD 
• bioMerieux SA
• F. HOFFMANN-LA ROCHE LTD.
• Lionex GmbH
• Oxford Immunotec Ltd
• QIAGEN
• Serum Institute of India Pvt. Ltd.

Europe Latent TB Detection Report Scope